SAN DIEGO, CA--(MARKET WIRE)--Jun 20, 2007 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has been engaged by GeoVax Labs, Inc. (OTC BB:GOVX.OB - News), an Atlanta-based biotechnology company, to manufacturer its HIV-1 DNA (AIDS) vaccine. This vaccine will be utilized in GeoVax's advanced Phase 2 human trials planned to start in early 2008. GeoVax chose Althea as the contract manufacturer for its DNA vaccine based on its extensive experience in the field of DNA vaccine manufacture and its regulatory compliance history.
